<SEC-DOCUMENT>0001176256-17-000083-index.html : 20170331
<SEC-HEADER>0001176256-17-000083.hdr.sgml : 20170331
<ACCEPTANCE-DATETIME>20170331110716
ACCESSION NUMBER:		0001176256-17-000083
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170331
DATE AS OF CHANGE:		20170331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NYMOX PHARMACEUTICAL CORP
		CENTRAL INDEX KEY:			0001018735
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12033
		FILM NUMBER:		17728677

	BUSINESS ADDRESS:	
		STREET 1:		9900 CAVENDISH BLVD., SUITE 306
		STREET 2:		ST. LAURENT
		CITY:			QUEBEC CANADA
		STATE:			A8
		ZIP:			H4M 2V2
		BUSINESS PHONE:		1-800-936-9669

	MAIL ADDRESS:	
		STREET 1:		9900 CAVENDISH BLVD., SUITE 306
		STREET 2:		ST. LAURENT
		CITY:			QUEBEC CANADA
		STATE:			A8
		ZIP:			H4M 2V2
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>nymox20f.htm
<DESCRIPTION>ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016
<TEXT>
Document 1 - file: nymox20f.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.A
<SEQUENCE>2
<FILENAME>exhibit12-a.htm
<DESCRIPTION>SOX SECTION 302 CEO CERTIFICATION
<TEXT>
Document 2 - file: exhibit12-a.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.B
<SEQUENCE>3
<FILENAME>exhibit12-b.htm
<DESCRIPTION>SOX SECTION 302 CFO CERTIFICATION
<TEXT>
Document 3 - file: exhibit12-b.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.A
<SEQUENCE>4
<FILENAME>exhibit13-a.htm
<DESCRIPTION>SOX SECTION 906 CEO CERTIFICATION
<TEXT>
Document 4 - file: exhibit13-a.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.B
<SEQUENCE>5
<FILENAME>exhibit13-b.htm
<DESCRIPTION>SOX SECTION 906 CFO CERTIFICATION
<TEXT>
Document 5 - file: exhibit13-b.htm

</DOCUMENT>
</SEC-DOCUMENT>